WYETH-LEDERLE ACEL-IMUNE RECOMMENDED FOR FIRST FOUR DOSES OF PRIMARY IMMUNIZA-TION SERIES; ADDITIONAL FIFTH DOSE SAFETY DATA NEEDED FOR APPROVAL
Additional fifth dose data will be needed to support the safety of Wyeth-Lederle's Acel-Imune (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) for use after four previous doses of the DTaP vaccine, FDA's Vaccines & Related Biological Products Advisory Committee agreed at an Oct. 29 meeting.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth